LabGenomics

Name

LabGenomics

Legal name

(주)랩지노믹스

Website

https://labgenomics.co.kr

Company type

Public

Founded year

2002

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Molecular Diagnostics and Clinical Laboratory Services

NAICS

Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF)

akta.pro secondary industries

Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Genetic & Prenatal Testing Laboratories (HLAFAMAH), Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ)

Keywords

• Molecular diagnostics services
• Genetic testing kits
• Non-invasive prenatal testing
• Cancer companion diagnostics
• Clinical laboratory services

Headquarters

HQ city

Bundangdong

HQ country

South Korea

HQ region

Asia

Offices6 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Clinical Laboratory Testing Services: Molecular and genetic diagnostic testing services provided to hospitals, clinics, and healthcare institutions. Revenue is recurring based on test volume. Includes NIPT (MomGuard), neonatal genetic tests, cancer companion diagnostics (OTD-Lung, OTD-Liquid), cytogenetics, flow cytometry, FISH, and IHC. US operations through QDx Pathology and IMD CLIA labs serve domestic US hospitals and Korean hospital networks via overseas referral testing.
2. IVD Diagnostic Kits and Reagents: Sale of molecular diagnostic kits (COVID-19, drug rapid antigen, ovulation/pregnancy, STIs), immunodiagnostic products, and genetic testing kits (DTC and medical). Also includes NGS reagents and cfDNA extraction kits for research and clinical use.
3. Overseas Licensing and Distribution: Export of diagnostic kits and licensing of technology/brand to international distributors. Includes NIPT MomGuard supply to Riva LAB in Greece, COVID-19 kit exports to Middle East, Europe, and Southeast Asia. Genome analysis reagent distribution rights via NEB partnership.
4. US CLIA Lab Outsourcing Services: Referral testing services for Korean hospitals and medical institutions via US CLIA-certified labs (QDx and IMD), enabling access to advanced diagnostics (NGS cancer panels, blood-based Alzheimer's tests) not available domestically.

Go-to-market motion2 records

Distribution channels7 records

Marketing channels6 records

Core offering

LabGenomics is a South Korea-based molecular diagnostics company that provides NGS-based genetic testing services and diagnostic kits. Core offerings include non-invasive prenatal testing (MomGuard), neonatal genetic screening (EnfantGuard), cancer companion diagnostics (OTD-Lung tissue biopsy, OTD-Liquid liquid biopsy), microbiome testing (BiOralCare oral, PinkBiomeCare vaginal), drug rapid antigen kits, and direct-to-consumer personal genome tests (WithGene). The company operates four CLIA-certified labs in the US and an AI-powered health risk prediction platform (EarlyQ), serving hospitals, OB/GYN clinics, dental clinics, US hospital networks, and individual consumers.

Differentiator

Problem solved

Functional benefit

Brands

• MamGuard (맘가드): NGS-based Non-Invasive Prenatal Test (NIPT) for prenatal screening
• WithGene (위드진)
• OTD-Lung (오티디-렁)
• OTD Liquid (오티디 리퀴드)
• BioRalCare (바이오랄케어)
• PinkBiome (핑크바이옴)
• PreMomGuard (프리맘가드)
• EarlyQ (얼리큐)
• Mesemble (메셈블)
• LabGun

Products and services

• MomGuard (맘가드) NGS-based Non-Invasive Prenatal Test (NIPT) for prenatal screening. Korea's first commercially available NGS-based NIPT, launched in 2015. Distributed in Greece, Albania, Macedonia, Turkey, and Bulgaria via Riva LAB.
• EnfantGuard (앙팡트가드) Neonatal genetic testing service for newborn developmental disorders and genetic disease screening. Combined with Kakao Healthcare's infant health management service.
• PreMomGuard (프리맘가드) NGS-based miscarriage cause analysis test.
• OTD-Lung (오티디-렁) NGS-based companion diagnostic test for non-small cell lung cancer using Thermo Fisher's Oncomine Dx Target Test panel. FDA-approved, requires half the sample of standard NGS panels, delivers results within 2 weeks. Provides approximately 43% medical cost reduction vs standard solid tumor Level 2 testing.
• OTD-Liquid (Liquid Biopsy) Liquid biopsy test for solid cancer stages 3-4 using IMBDx AlphaLiquid 100 panel. Analyzes blood for genetic mutations enabling personalized treatment when tissue biopsy is not feasible.
• WithGene (위드진) Direct-to-consumer (DTC) personal genetic characteristic test covering 63 genetic traits including hair loss, obesity, blood sugar, and skin. Sold through e-commerce, pop-up stores, home shopping, and corporate wellness platforms.
• BiOralCare (바이오랄케어) Oral microbiome testing service analyzing beneficial and harmful bacteria species and distribution in the oral cavity. Supplied to Denhau Dental Hospital, Seoulhoon Dental Group (MediCl/Korea's largest dental franchise), Banksalad platform, and Hyundai Department Store pop-ups.
• PinkBiome (핑크바이오) Vaginal microbiome testing service analyzing beneficial and harmful bacteria in the vaginal area for personal hygiene management.
• EarlyQ (얼리큐) AI-powered health risk prediction platform analyzing health insurance data, family medical history, insurance information, and health examination data from 500 million data points across 1 million Korean health records over 12 years to predict disease risk and recommend nutrients.
• Mesemble (메셈블) AI-based cancer disease analysis platform using DNA methylation for cancer detection and diagnosis.
• Rapid Antigen Drug Detection Kit (6 types) Rapid antigen test kits detecting 6 drug types (Methamphetamine, Cocaine, Opiate, Marijuana, Ecstasy, Ketamine) through urine samples in 10-15 minutes. Received MFDS (Korean FDA) certification in August 2025. Government bid participation capability acquired.
• LDT GPP (Gastrointestinal Pathogen Panel) 2nd LDT product: Gastrointestinal Pathogen Panel registered in New Jersey State, USA. Developed in collaboration with Atopplex. Estimated 50% cost reduction compared to existing products. Follows FDA-level rigorous registration procedures.
• LDT RPP Essential (Respiratory Pathogen Panel) First Laboratory Developed Test (LDT) registered at US CLIA labs (QDx) for the US market. Respiratory pathogen panel for respiratory infection diagnostics.
• Cell-free DNA Isolation Kit (LabGTM) High-purity cfDNA extraction reagent from blood for liquid biopsy applications. Certified for domestic use. Supports the OTD-Liquid biopsy workflow.
• LabGun Diagnostic Kits Molecular diagnostic kit brand including COVID-19 and other infectious disease test kits. Exported globally during the pandemic.
• US CLIA Lab Testing Services (QDx Pathology & IMD) Clinical laboratory testing services provided through four CLIA-certified labs in the US: QDx Pathology (New Jersey) and IMD labs (Sacramento, Aurora, Berkeley). Services include NGS-based cancer testing, myeloid panel for leukemia/lymphoma, flow cytometry, FISH, IHC, dermatopathology, and pathology testing. Faster TAT (24-48 hours at QDx vs industry average).
• Blood-based Alzheimer's Diagnostic Service (Lumipulse) Blood-based Alzheimer's diagnostic service using Lumipulse (Fujirebio, FDA-approved May 2023) measuring tau protein and beta-amyloid biomarkers. Provided in Korea and via overseas referral testing through US CLIA labs in collaboration with Daewoong Bio.

Quantifiable outcome

• NIPT market leader in Korea with first-to-market MomGuard (2015)
• +7 more outcomes

Named customers15 records

Segments4 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature8 records

Partnerships

29 partnerships are on record, tiered core, major and minor.

• Daewoong BiocoreStrategic or Co-development Partner · 15 June 2026Daewoong Bio and LabGenomics are collaborating to introduce blood-based Alzheimer's disease diagnostic technology (Lumipulse, Fujirebio) to Korea. LabGenomics provides the diagnostic platform and overseas referral testing services via US CLIA labs for domestic medical institutions.
• QDx PathologycoreStrategic or Co-development Partner · 15 June 2026LabGenomics subsidiary QDx Pathology provides overseas referral testing services for Daewoong Bio's Alzheimer's diagnostic platform (Lumipulse). QDx serves as the US-based testing hub for Korean patients seeking advanced diagnostics.
• QDx Pathology Services (Acquisition)coreTechnology or Integration · 11 May 2026LabGenomics USA acquired QDx Pathology Services (100% stake) in August 2023 for ~768 billion KRW. QDx is a CLIA-certified pathology lab in New Jersey, providing pathology testing, flow cytometry, and serving as base for LDT test registration. Unified under LabGenomics brand in May 2026.
• Yutu Medical FoundationmajorChannel Partner/ Reseller/ Distributor · 24 March 2026LabGenomics signed MOU (March 2024) and main service contract (April 2025) with Yutu Medical Foundation for specimen outsourcing business. Partnership strengthens testing operational stability, expands service capacity, and enhances customer trust. Aims to broaden testing coverage and market competitiveness.
• Adventist HealthcoreStrategic or Co-development Partner · 24 February 2025IMD signed service supply agreement with Adventist Health, a major US integrated delivery network (IDN) with 100+ community healthcare sites and 440+ facilities in the western US and Hawaii. IMD provides NGS-based cancer testing and myeloid panel testing (leukemia, lymphoma) to 4+ hospitals starting with St. Helena and Glendale in California. Contract followed ~3 years of negotiations.
• Bio-Reference Laboratories (GenPath Diagnostics)majorStrategic or Co-development Partner · 13 December 2024LabGenomics signed service agreement with Bio-Reference Laboratories, a top US CLIA-certified clinical lab (established 1981, 3Q 2024 cumulative revenue ~$529M). LabGenomics provides cancer and urology testing services in NY/NJ region via GenPath Diagnostics subsidiary. First major US market contract demonstrating market presence.
• Orange County Pathology Medical Group (OCPMG)majorStrategic or Co-development Partner · 9 December 2024IMD signed service agreement (SLA) with OCPMG, a large pathology group in Orange County, California with 50+ years of history. IMD provides Flow Cytometry and FISH pathology testing (TC/PC) for dermatopathology, including Her2/Neu FISH analysis for breast and gastric cancer. First contract following IMD acquisition.
• Kakao HealthcareminorStrategic or Co-development Partner · 18 November 2024LabGenomics introduced Kakao Healthcare's continuous glucose monitor (CGM) and infant health management service 'EnfantGuard' at Korean Society of Pediatric and Adolescent Medicine academic conference. Combined LabGenomics' genetic testing with Kakao Healthcare's digital health platform.
• Daewoong BiominorStrategic or Co-development Partner · 18 November 2024Daewoong Bio hosted 'Yeondoo Symposium' in June 2026 where LabGenomics presented its blood-based Alzheimer's diagnostic services using Lumipulse (Fujirebio). Daewoong Bio and LabGenomics plan to expand overseas referral testing services for Korean medical institutions.
• Integrated Molecular Diagnostics (IMD) CLIA Labs (Acquisition)coreTechnology or Integration · 25 October 2024LabGenomics USA completed acquisition of IMD CLIA labs in October 2024, increasing total CLIA-certified labs to 4. IMD has 3 labs in Sacramento, Aurora, and Berkeley. Specializes in molecular technology and cancer diagnostics. Unified under LabGenomics brand in May 2026.
• BanksaladminorGTM or Marketing Partner · 10 May 2024DTC genetic testing services (WithGene personal genome test, BiOralCare oral microbiome test) supplied to Banksalad's platform. Plans for oral microbiome testing with 19 disease-related items. Banksalad's digital platform enables consumer access to LabGenomics' genetic tests.
• Kakao HealthcaremajorStrategic or Co-development Partner · 5 April 2024LabGenomics and Kakao Healthcare signed obstetrics and gynecology diagnostic cooperation agreement. Initial focus: continuous glucose monitoring (CGM) for gestational diabetes management using Kakao Healthcare's Pasta platform. Combines LabGenomics' MomGuard, EnfantGuard, and other OB/GYN products with Kakao Healthcare's digital health platform. Plans to leverage Dexcom CGM technology.
• New England Biolabs (NEB)minorChannel Partner/ Reseller/ Distributor · 1 April 2024LabGenomics signed genome analysis reagent distribution agreement with NEB in December 2023. LabGenomics showcased NEB products at KSMCB Epigenetics Symposium (December 2024) and HGM 2024 in Italy, promoting NGS services and NEB reagents to Korean researchers.
• NovaRecminorStrategic or Co-development Partner · 8 February 2024Collaboration with NovaRec (health functional food company) to complete AI algorithm development for gene-based health supplement recommendations. Combines LabGenomics' genetic analysis with NovaRec's health supplement products for personalized nutrition recommendations.
• ImcoG and PeopleBiominorStrategic or Co-development Partner · 5 November 2023Joint participation in Korean Dementia Society academic conference with ImcoG (digital cognitive testing) and PeopleBio (genetic/blood marker testing). Promoting comprehensive dementia diagnosis and treatment platform: amyloid antibody therapy, blood biomarkers, PET imaging, AI brain imaging, health checkup linkage, and online cognitive testing.
• Eight Healthcare Companies (Korean Dementia Society)minorStrategic or Co-development Partner · 5 November 2023Eight healthcare companies including LabGenomics participated in Korean Dementia Society special symposium, offering a comprehensive dementia diagnosis and treatment solution: amyloid antibody therapy (Korea Ezai), blood markers/genomics (LabGenomics, PeopleBio), PET imaging solutions (Brightonics Imaging), PET radiopharmaceutical development (DuChem Bio), brain disease AI imaging (Neurophet), health checkup linkage (GC Care), and online cognitive testing (ImcoG).
• DxomeminorStrategic or Co-development Partner · 14 April 2023MOU with Dxome (liquid biopsy company) to supply ct-DNA based cancer companion diagnostic and prognosis monitoring panels to LabGenomics' US CLIA lab. Dxome's Pan100 and TMB500 panels already commercialized in Korean major hospitals. Dxome CLIA Laboratory was established in the US in 2020.
• NovomixminorStrategic or Co-development Partner · 12 April 2023LabGenomics participated in Novomix's equity offering to strengthen US business collaboration. Novomix and LabGenomics had previously signed an MOU (March 2023) for US market expansion cooperation.
• GencuricsminorStrategic or Co-development Partner · 27 March 2023Business cooperation agreement with Gencurics to launch molecular diagnostic services in the US market. Gencurics provides its diagnostic content (test panels) which LabGenomics introduces to its CLIA lab operations.
• EngenbiominorStrategic or Co-development Partner · 19 January 2023MOU with Engenbio (NGS precision diagnostics platform company) for NGS-based precision diagnostic service development and US market entry. Plans: CLIA lab NGS LDT service development and US commercialization; joint development of early diagnosis to prognosis prediction solutions.
• MediClminorChannel Partner/ Reseller/ Distributor · 21 December 2022Business cooperation agreement with MediCl for joint domestic hospital market activities. MediCl operates Seoulhoon Dental Group (Korea's largest dental franchise) and MDI network, through which LabGenomics' BiOralCare oral microbiome test is distributed.
• Human ScaveminorGTM or Marketing Partner · 20 December 2022MOU with Human Scave for overseas market expansion. LabGenomics made a strategic equity investment in Genoscape (Human Scave's Singapore subsidiary) to leverage Scave's Mamitalk pregnancy/parenting app (100K+ users in Indonesia) for DTC genetic testing distribution in Southeast Asia.
• Maryland State Government (Governor Larry Hogan)minorOthers · 11 October 2022LabGenomics engaged with Maryland State (governor Larry Hogan, known as 'Korean son-in-law') for US market investment and partnership. Maryland is a major biotech cluster home to FDA, NIH, NCI, EPA, and Johns Hopkins University. LabGenomics planned to establish its own CLIA lab and GMP facility in Maryland.
• AbiONminorStrategic or Co-development Partner · 5 October 2022MOU with AbiON (anti-cancer drug development company) to develop liquid biopsy-based companion diagnostic kits and clinical services for anti-cancer drug development. LabGenomics invested in AbiON's convertible bond issuance (April 2023).
• Rockwon Bio Convergence Research FoundationminorStrategic or Co-development Partner · 30 September 2022MOU for liquid biopsy-based cancer early diagnosis and prognosis prediction. Rockwon Foundation (spin-off from Seoul National University Cancer Companion Diagnostics program) provides companion diagnostics R&D and biomarker analysis expertise.
• IntinminorStrategic or Co-development Partner · 29 August 2022Strategic MOU with Intin (digital healthcare company specializing in home fertility testing devices) for in vitro diagnostic medical device R&D, digital healthcare product distribution in Korea, and joint commercialization.
• GoodocminorGTM or Marketing Partner · 26 August 2022Strategic MOU with Goodoc (mobile healthcare platform, 10M+ downloads) for digital healthcare business development. Plans: diagnostic and genomic data integration, PHR service development, AI-powered personalized digital healthcare.
• GenocoreBScoreStrategic or Co-development Partner · 19 November 2021LabGenomics acquired a 48.5% stake in GenocoreBS, an AI-based genetic analysis service company, to expand Personal Genome Analysis (PGS) services using AI platform technology. Goal: enhance early diagnosis and personalized health solutions through integrated AI and genetic analysis platforms.
• Daewoong PharmaceuticalminorStrategic or Co-development PartnerRyu Jae-hak, former Daewoong Pharmaceutical CH (Consumer Healthcare) Division head, was appointed Vice President (January 2025) and then Representative Director (June 2025) of LabGenomics. Brought 20+ years of pharmaceutical marketing, BD, R&D, and healthcare sales experience. Strategic hire to strengthen diagnostic sales organization using pharmaceutical best practices.

Scale indicators14 records

Recent moves7 records

Expansion highlights7 records

Regional players

• ImpediMed: Australia-based bioimpedance spectroscopy diagnostics company with operations in US. Comparable as a smaller specialty diagnostics company that has successfully entered the US clinical market with a focused test menu, relevant as a model for LabGenomics' US specialty diagnostic expansion.

Direct peers

• Seegene: South Korea's leading molecular diagnostics company developing PCR-based IVD kits for infectious disease and cancer. Comparable as a Korean molecular diagnostics company with a similar product mix (IVD kits, COVID-19 exports) competing in the same global markets.
• NeoGenomics: US-based oncology-focused clinical laboratory providing NGS cancer panels, flow cytometry, FISH, and pathology services. Highly comparable to LabGenomics' IMD/QDx operations serving similar US hospital customers with similar oncology and pathology test menus.
• Guardant Health: US liquid biopsy leader with FDA-approved Guardant360 CDx for solid tumor genomic profiling. Comparable to LabGenomics' OTD-Liquid liquid biopsy service and the broader cancer companion diagnostics strategy targeting the same US oncologist and hospital customers.
• Natera: US molecular diagnostics company with Signatera MRD test and Panorama NIPT. Comparable as a molecular diagnostics company operating across NIPT and oncology, both areas where LabGenomics (MomGuard, OTD-Lung) competes directly.
• Macrogen: Korean genomics services company offering NGS, whole genome sequencing, and microarray services. Directly comparable as a Korean-headquartered molecular/genomic diagnostics provider with overlapping NGS service offerings, B2B academic/clinical customers, and global distribution.

Broad incumbents

• Laboratory Corporation of America (LabCorp): US clinical laboratory giant offering full menu of routine and esoteric testing. Relevant as the dominant incumbent LabGenomics competes with for US hospital IDN contracts, with massive scale advantages in logistics, billing, and IT integration.
• Bio-Techne: US life sciences tools and diagnostics company with reagents, ELISA kits, and emerging diagnostic applications. Comparable in the reagents and proteomics side, and a relevant partner/competitor in the genomic/biomarker supply chain that LabGenomics' CLIA labs use.

Emerging players

• Veracyte: US genomic diagnostics company focused on urology, thyroid, and lung cancer. Comparable to LabGenomics' OTD-Lung companion diagnostic and broader cancer NGS strategy, with a similar model of partnering with hospital networks and IDNs.
• Genolution: Korean molecular biology company specializing in nucleic acid extraction reagents and instruments. Direct technology partner/comparable in the Korean molecular diagnostics supply chain; LabGenomics has a cooperation agreement with Genolution for extraction reagents used in NGS services.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@labgenomics
• LinkedInlinkedin.com/company/labgenomics

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries5 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LabGenomics